NCT04469244: RADDOPAG

Evaluation of the Use of Radiomics in 18F-FDOPA PET Examinations for the Characterization of Gliomas

Completed Last updated 24 August 2022

What this trial tests

trial in Study on the Use of Radiomics in Gliomas of Initial Disgnosis in 1,000 participants. Completed in 20 October 2020.

Timeline

1 July 2020

Primary endpoint
3 August 2020

20 October 2020

Quick facts

Lead sponsor	Central Hospital, Nancy, France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	1 July 2020
Primary completion	3 August 2020
Estimated completion	20 October 2020
Sites	1 location across France

Conditions studied

• Study on the Use of Radiomics in Gliomas of Initial Disgnosis — all drugs for Study on the Use of Radiomics in Gliomas of Initial Disgnosis →

Sponsor

Central Hospital, Nancy, France

Who can join

Eligibility, any sex, with Study on the Use of Radiomics in Gliomas of Initial Disgnosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The evaluation of gliomas in imaging represents a real challenge today, at the initial diagnosis, for therapeutic planning or follow-up treatment of these lesions. There is an urgent need for non-invasive imaging tools to evaluate a glioma throughout its management. At present, the diagnosis of certainty is only obtained through an anatomo-pathological analysis with sampling during an invasive procedure (surgery or biopsy). Magnetic resonance imaging, through perfusion, diffusion imaging or spectroscopy is developing in gliomas. However, it remains time-consuming and is not always available. At the same time, positron emission tomography (PET) with amino acids is an interesting alternative for these brain tumours. Amino acid PET has the advantage of being more specific than the abnormalities detected in MRI and the amino acid radiotracers cross the blood-brain barrier, even if not broken, unlike Gadolinium in MRI. Among these radiotracers, 18F-FDOPA can, among other things, assist in the non-invasive staging of gliomas at initial diagnosis.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. ¹⁸F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study.
   Zaragori T, Oster J, Roch V, Hossu G, et al · · 2022 · cited 51× · PMID 34016731 · DOI 10.2967/jnumed.120.261545
2. Effects of Carbidopa Premedication on ¹⁸F-FDOPA PET Imaging of Glioma: A Multiparametric Analysis.
   Bros M, Zaragori T, Rech F, Blonski M, et al · · 2021 · cited 14× · PMID 34771504 · DOI 10.3390/cancers13215340
3. Relevance of Dynamic ¹⁸F-DOPA PET Radiomics for Differentiation of High-Grade Glioma Progression from Treatment-Related Changes.
   Ahrari S, Zaragori T, Rozenblum L, Oster J, et al · · 2021 · cited 13× · PMID 34944740 · DOI 10.3390/biomedicines9121924
4. Application of PET imaging delta radiomics for predicting progression-free survival in rare high-grade glioma.
   Ahrari S, Zaragori T, Zinsz A, Oster J, et al · · 2024 · cited 7× · PMID 38332004 · DOI 10.1038/s41598-024-53693-x
5. Implementing the Point Spread Function Deconvolution for Better Molecular Characterization of Newly Diagnosed Gliomas: A Dynamic ¹⁸F-FDOPA PET Radiomics Study.
   Ahrari S, Zaragori T, Bros M, Oster J, et al · · 2022 · cited 7× · PMID 36497245 · DOI 10.3390/cancers14235765
6. Dynamic ¹⁸F-FDopa PET Imaging for Newly Diagnosed Gliomas: Is a Semiquantitative Model Sufficient?
   Zaragori T, Doyen M, Rech F, Blonski M, et al · · 2021 · cited 6× · PMID 34676168 · DOI 10.3389/fonc.2021.735257
7. Amino-acid PET as a prognostic tool after post Stupp protocol temozolomide therapy in high-grade glioma patients.
   Zinsz A, Ahrari S, Becker J, Mortada A, et al · · 2024 · cited 5× · PMID 38842696 · DOI 10.1007/s11060-024-04722-2